CARB-X

CARB-X funding round #1, SDRI 2017, & Antibiotic-tainted seafood

Dear All: Just in case you missed the 30 March annoucement, see at right a snapshot of the first 11 Powered by CARB-X funded companies. Initial funding is $24m, with  potentially a further $24m if the companies hit their milestones. With the funds provided by the companies themselves, the total potential investment is $75m. This is just the start:

Read More »

CARB-X is seeking additional accelerators to expand support for its pipeline

Dear All: It is exciting to see that CARB-X today announced that it is seeking to partner with up to 6 additional accelerator organizations to expand its drug development and business support for its growing pipeline of early development antibacterial research projects. The Powered by CARB-X portfolio currently has 22 active projects in its pipeline, with more project announcements

Read More »

Clostridioides difficile / CARB-X Year 3 Annual Report / White House OSTP seeks input on the US Bioeconomy

Dear All, Committing serial email this afternoon… First, the note I just sent on FMT for Clostridium difficile (link) prompted comments that the organism is now called Clostridioides difficile. This name change slipped past me, I’ll admit! But it does seem a settled change … see this helpful editorial from May 2019 in Lancet ID for a summary of how the new

Read More »
Scroll to Top